Former OpenAI executive Fidji Simo launches ChronicleBio, an AI-powered startup using home blood draws and 153 terabytes of biological data to identify chronic disease sub-groups and improve clinical drug trial success rates.
A consortium of AI companies including Loka, AWS, and Arcee AI releases Trinity Mini, an open 26-billion-parameter biomedical reasoning model trained with reinforcement learning that achieves 81.2% drug evaluation accuracy, offering organizations an auditable, deployable solution for specialized scientific AI within controlled infrastructure.
Google DeepMind has quietly disbanded its Nobel Prize-winning AlphaFold team less than a year after its historic 2024 Nobel Prize, with key researchers including Nobel co-winner John Jumper defecting to rival Anthropic, which just launched Claude Science to target the biology and drug-discovery space AlphaFold helped pioneer.
AI is slashing drug development costs by up to 70% and driving a projected $1 billion surge in new biopharma spending, but critics warn that no AI-discovered drug has yet received FDA approval, and the industry's notorious 90% failure rate may persist if human biological variability isn't properly addressed before …
Anthropic launches an internal drug discovery program targeting neglected diseases and unveils Claude Science, a new AI tool for drugmakers, positioning itself as a hands-on healthcare player alongside tech giants like Alphabet, Apple, and Amazon.
Google Cloud launches SandboxAQ's quantitative AI models and a new Gemini for Science suite, giving enterprise and research teams powerful tools to accelerate drug discovery, materials science, and semiconductor R&D by combining scientific numerical AI with Gemini's reasoning capabilities.
NVIDIA launches its Agent Toolkit, an open and modular platform empowering enterprises to build specialized AI agents with secure, customizable tools already achieving 98.5% alert accuracy in cybersecurity and accelerating drug discovery across major platforms like SAP, Siemens, and ServiceNow.
NVIDIA's BioNeMo Agent Toolkit is revolutionizing biomolecular research by doubling AI token efficiency and achieving a perfect 100% task completion rate, up from 57.1%, by packaging complex scientific models into autonomous, callable AI tools.
Biohub launches a groundbreaking open-source AI protein biology platform featuring three powerful tools that outperform AlphaFold 3 in antibody-antigen prediction, design cancer-targeting protein binders with up to 88% lab-validated hit rates, and make 6.8 billion protein sequences searchable to accelerate global scientific discovery.
Runway, now valued at $5.3 billion, is pivoting from AI filmmaking tools to building world models designed to simulate physical environments, targeting transformative applications in robotics, drug discovery, and climate modeling — but faces stiff competition from Google, OpenAI, and compute resource challenges.